Ladies and gentlemen, good day, and welcome to Rossari Biotech Limited earnings conference call. As a reminder, all participant lines will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Ayesha Shah from CDR India. Thank you, and over to you. Good afternoon, everyone. Thank you for joining us on Rossari Biotech Q3 and nine-month FY 2023 earnings conference call. We have with us Mr. Edward Menezes, Promoter and Executive Chairman, Mr. Sunil Chari, Promoter and Managing Director, Mr. Ketan Sablok, Group Chief Financial Officer, and Ms. Manasi Nisal, Chief Financial Officer. We will begin the call with opening remarks from the management, following which we will have polling open for question and answer session. Before we start, I would like to point out that some statements made in today's call may be forward-looking in nature, and a disclaimer to this effect has been included in the earnings presentation shared with you earlier. I would like to invite Mr. Edward Menezes to make his opening remarks. Thank you. Over to you, sir. Thank you, Ayesha. Good evening, everyone. Thank you for joining us on our Q3 and nine-month FY 2023 earnings call to discuss the operating and financial performance for the quarter. I hope you all had the opportunity to go through our results presentation, which provides details of our operational and financial performance. We have reported a stable performance during the quarter despite the ongoing challenging operating environment. All our standalone segments, including HPPC, Textile, and AHN, have reported a stable performance. However, our subsidiaries witnessed a slowdown due to subdued demand, leading to lower consolidated sales during the quarter. During the quarter, we were able to improve our margin performance both on a QoQ and on a YoY basis as a result of moderating raw material prices. Our focus continued on prioritizing products with better margins, which has resulted in improved profitability. As the market begins to stabilize, we should see improved performance moving forward. The company has been committed to the development of green and sustainable chemicals since its inception. This focus on sustainability is part of the company's identity, and we have invested in R&D to create a range of eco-friendly products over the years. Given the global shift towards environmentally friendly solutions, we hope to capitalize on our investments as well as help create a healthier and more sustainable future. With this, I would like to conclude my address, and I now hand it over to Mr. Chari for his comments. Thank you, Edward Menezes. Good evening and a warm namaste to everyone. Q3 remained a challenging quarter for us, with our subsidiaries facing some slowdown. At a standalone level, we have maintained our revenues while improving our margin performance. As the operating environment stabilizes, we believe we are well equipped to pursue high growth opportunities given our comprehensive product offerings, flexible capacities, and R&D capabilities. Our acquisitions have expanded our presence into new regions and product categories, further broadening our growth horizons. Our commitment to R&D has been instrumental in establishing Rossari as a leading specialty chemicals manufacturer, providing intelligent and sustainable solutions. With a proven track record of developing innovative and tailored chemical solutions for customers across multiple industries, we aim to expand our customer base in our existing segments while also exploring new industries such as water treatment, paper, ceramic, and cement. Our recent launches in these industries have received favorable responses, and we are optimistic about achieving growth in these segments in the coming years. The specialty chemicals industry in India is poised for subsequent significant growth in the coming years, driven by factors such as increasing demand for specialized chemicals in various end-use industries and a shift towards sustainable solutions. Despite the industry facing some near-term headwinds, the long-term outlook remains positive and intact. The Indian government support for the growth of the domestic specialty chemical sector is also a positive factor. In the long run, we believe that the specialty chemicals industry in India presents a bright future and offers promising opportunities for growth. On this note, I would now request Ketan sir to share his perspectives. Thank you, Chari Sir, and good evening to everyone. Rossari performed steadily during this quarter on a standalone level, despite the pressures we experienced in previous quarters. Our subsidiaries witnessed a slowdown in Q3 due to decreased demand, which resulted in lower sales on a consolidated basis. However, I am happy to say that post-acquisition on a nine-month basis, both our subsidiaries have done exceptionally well, both in terms of top line as well as the margins. We have been able to synergize the business between the group companies very well, be it in operations, sales, R&D, and new business development. The impact of this will further be visible over the next few years. We continue to focus on expanding our high margin product portfolio. This was evident in our improved gross margins and EBITDA over the last few quarters. Our gross margins have improved to reach 30% in Q3 FY 2023 compared to 25% in Q3 FY 2022. The improvement is visible in the standalone business also, with the gross margin moving up from 22% in Q3 FY 2022 to 29% in Q3 FY 2023. Furthermore, our EBITDA margins also improved to reach 14% compared to 11% in Q3 FY 2022. The uptick in margins is clearly visible both in the standalone and the consolidated business. Rossari's financial position continues to remain robust. A solid balance sheet, positive cash flows, and other inherent strengths will enable the company to continue its growth trajectory in the coming quarters. Overall, we remain confident in our ability to deliver long-term value to our stakeholders through our focus on profitability, innovation and growth. That's all from my side. I would now request Manasi to take you quickly through the financials for the quarter and nine months, and then we will open the forum for the Q&A. Thank you. Thank you, Ketan sir. Good evening, everyone. Let me provide you with a brief overview of the financial performance for the quarter ended December 31, 2022. On a consolidated basis, revenues came in at INR 389 crore as against INR 428 crore in Q3 FY 2022. On a standalone basis, revenues from operations stood at INR 237 crore compared to INR 268 crore in Q3 FY22. Revenues from HPPC stood at INR 271 crore, contributing to 69.7% of revenues, followed by textile businesses at INR 89.5 crore, contributing to 23% and H&N at INR 28.6 crore, contributing to 7.3% of total revenues on a consolidated basis. On a standalone basis, EBITDA stood at INR 32 crore as against INR 28 crore in Q2 FY23. PAT during the quarter stood at INR 17.5 crore as against INR 15.4 crore in Q2 FY23. On a consolidated basis, EBITDA stood at INR 54.2 crore as against INR 56.5 crore in Q2 FY 2023. PAT during the quarter stood at INR 25.7 crore as against INR 23.9 crore in Q2 FY 2023. On that note, I come to the end of my opening remarks and would request the moderator to open the forum for any questions that you may have. Thank you. Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and 1 on their touchtone telephone. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. We have our first question from the line of Sanjesh from ICICI Securities. Please go ahead. Good afternoon, sir. Thanks for taking my question. I've got few of them. Hopefully I don't exceed the time. Starting with the revenue side, can you explain us the standalone revenue go on a lower base. It has been flattish, and Q3 is generally a stronger quarter. Annualized Q3 number, we are still significantly lower than what we did in the FY 2022. In the same context, can you help us understand what was the volume growth? Because I know that, the prices have been falling because of the softening of raw material prices, so it doesn't give the right picture. To understand it better, two things. Can you help us understand the volume? Second, I also request, I know you don't give the sub-segmental number, but can you just broadly help us understand how our ingredient, private label, HPPC and Performance Chemicals are doing in the standalone? That's my first question. Hi, Sanjesh. On the standalone business, we've been really stagnant on the quarter-on-quarter performance. I think the one segment that has seen some headwinds is the textile chemical division. We are seeing a little slowdown on the textile sector, and that's impacting the CFC business of ours. That's one of the reasons why we've not seen a real growth coming on the standalone. Secondly, on the HPPC, we've been able to maintain our run rate on the standalone business, even though we had some headwinds in with at least one of the customers. We've been able to cover that to a larger extent, with some new customer additions, especially one key MNC that we've added in the last quarter. I think that's helping us play out quite well and helping us cover this business loss which we've had. I think going forward, I think in the next couple of quarters, we should be in a position to negate this loss in an entirety. AHN we are seeing good growth year-over-year almost 20% growth we've seen Q1, Q2 a bit unusual timing. We expect the momentum in this division to continue, and we are expecting Q4 in AHN to be stronger. Going forward, going to the next year, we expect this business to grow significantly, at least anything between 30%-35% kind of growth we are expecting in the AHN. Though it's a small base business, it's a high value and high margin business for us. That's on the standalone. If you have anything else on the standalone I can clarify. Just one follow-up. Ketan, can you help us on quarter-on-quarter volume growth? Because I think prices have softened, so the stable revenue is not the right picture, right? That's number one. Number two, the customer we spoke about, where there is a headwind, is it completely zero or there is more impact, which may likely come in the next quarter? Can you come on the second part again? I missed out. Sanjesh. second part is on the one customer- Sanjesh, you have to be a little louder, please. Now am I good now? Now it's better. Okay. Just on the one customer, where we spoke about a headwind in terms of the run rate, which has hurt the standalone business. Is that customer entirely zero or there is some more revenues to be knocked off from the base which need to be recouped with a new customer? How should we see that? No. The run rate with that customer now is completely zero. [uncertain], is zero. That headwind is no more going into the next quarter, right? No, no. Okay. In terms of volume growth in the standalone? I think, some amount of volume growth has been there. HPPC, as I said, we've been able to cover up most of this volume which we lost out because of this customer. Otherwise, we've not seen any volume drop. Textiles is largely quarter-on-quarter, I think, is mostly impacted due to softening of prices because RM prices have kept coming down. Got it. Got it. Second on the subsidiary part of the business where we have declined 18% from a seasonally weak quarter, which was in Q2. In general, agrochemical per se is doing fantastic. If you look at agrochemical companies number, there at least it doesn't shows like there is an headwind from the industry perspective. Can you help us understand why Rossari has had a very muted quarter this quarter? Historically, Sanjesh, Historically, agro season is strong in the first two quarters for last 30 years for Unitop. The third quarter is always, you know, little weak. Third and fourth quarters are weak for Unitop. If you see quarter on quarter, year- on- year... Even on a YoY basis. Quarter three of last year, Unitop has done very well in spite of RM prices falling and SG prices falling. No. Basically my question was that even on a YoY basis it's down 5%, while if you look at the industry growth it's. Because the raw material prices have fallen, substantially, I think more than 15%, finished goods prices have fallen. We've done well, you know, comparatively. Understand that. Yes, Sanjesh. Volume growth, if you can help us on that, in the subsidiary business. Subsidiary business quarter on quarter, Sanjesh, as Sarish has said, Unitop volumes and Tristar volumes have been slightly impacted. One, because Unitop, the agro season, is as he said generally is in the first half. We expect that to now pick up from mid-Feb onwards. In Tristar, we've seen little headwinds in our exports to Europe and probably also to Russia. That developed slowdown around November and December in these exports. Late December, the exports have picked up again and I think in this quarter we should see Tristar coming back to its quarterly run rate. These two have impacted our overall subsidiary volumes. Got it. Got it. Follow-up on the guidance. We guided that in FY 2023 we will achieve INR 20 billion of revenue and INR 2.5 billion of EBITDA. In current context, it looks like, slightly challenging. Are we updating on the guidance and how should one look at FY 2024 in that context? Yeah. Given the way the second half has panned out, I don't think we are going to hit that number of INR 2,000 crores. Going by the current run rate, I think we should be closer to about INR 1,650, INR 1,700 crores around that number. Around INR 1,700 crores topline we should be closing this year. EBITDA, sir? EBITDA. EBITDA we should be at about INR 220-230 crores kind of an EBITDA we should be able to do. Anything you want to talk about FY 2024 now that the base is also favorable? Is it fair to assume that next year we should be doing upwards of 20% in terms of revenue and EBITDA? Yeah. We are looking at FY 2024 to at least give us a 15%-20% kind of a growth on the top line with better margin profile. That's how we are looking at it now. Now that the raw material prices have corrected, the base effect is not there. We should be sparsely moving towards the 17%-18% EBITDA margin, which we were doing earlier in next 1-2 years. That is fairly possible right now? Yes. I cannot say that for the next year, but yes, we are moving towards that. You see our numbers are slowly improving. Over the next two years we should get back to our 16%-17% kind of, levels. We should be there. Got it. Thanks, Ketan ji. Thanks, Chari ji, for all the answers and best of luck for the coming quarters. Thank you, Sanjesh. Welcome, Sanjesh. Thank you. Ladies and gentlemen, to ask a question, please press star and one on your phone. Participants are requested to press star and one to ask a question. We have a question from the line of Rohit Nagraj from Centrum Broking. Please go ahead. Yeah. Thanks for the opportunity, and good afternoon, sirs. Sir, first question is again on the subsidiaries front. Is there any element of inventory destocking at customers' end, and that has impacted our volumes? Probably, this phenomena can continue for a quarter, couple of quarters and which may have further impact on the volumes. Thank you. Yeah. I think it is visible in Tristar, where, you know, we saw some slowdown on the export side in this quarter. That what we understand was a phenomenon of destocking which is happening in the customers. We expect that to get normalized at least by mid of this quarter. We should be doing a little better in Tristar in Q4. For Unitop, any comments? Unitop we are not seeing anything on this. In fact, our non-agro business in Unitop has done pretty well. We are quite happy with that. We've seen a good growth in the non-agro part of Unitop. Right. Got it. sir, second question is on the, Textile Specialty. In the last, three, four quarters, we have seen that there have been multiple headwinds because of which, this particular segment has not done well. Any green shoots that we are seeing, from the demand perspective or the segment now, you know, picking up and probably in a quarter, couple of quarters, things will start looking substantially better? Thank you. Namaste, Rohit. I'm Chari here. Textile industry we are seeing, you know, still some slowdown in this quarter. Indications are that from May, June onwards, again, demand should pick up very well. This year, you know, the domestic demand was good, but the export demand was muted for all good exporters, which you can see in the results of the textile companies also. We feel, you know, we are seeing exports picking up for Rossari, for the textiles, and we think the next financial year we should do better than this year. Right, sir. got it. thanks a lot for answering all the questions and best of luck. I'll come back in the queue. Thank you. Thank you, Rohit. Thank you. Ladies and gentlemen, to ask a question, please press star and one on your phone. Participants may please press star and one on their phone to ask a question. Participants may please press star and one to ask a question. As there are no more questions, I now hand the conference over to the management for closing comments. Over to you. I'm sorry, there is one question. Should I go ahead, sir? Yes, yes. We have a question from Palak Shah from Infina Finance. Please go ahead. Yes. Hi, sir. Thank you for taking my question. Just incrementally, we've been discussing for the last two quarters that we are now focusing more on the higher margin business. In that context, when you look at a new order or new chemistry, what's the benchmark margins that you actually focus on? Good afternoon, Mr. Palak. I'm Edward here. All our new projects are always targeted to 20% EBITDA. Now of course, this depends on the market and the competition. But most of the projects that we started, they would be at least 30%+ gross margins and about 18%-20% EBITDA. That is how we look at our new projects. However, having said that, we have a few aces up our sleeves, like a green surfactant or the, you know, silicone-based wetting agents that we've developed recently, as well as some of the products in spin finish. In our production of, you know, esters, et cetera, where the margins will be higher. Very consciously, we have taken a decision to promote the Animal Health and Nutrition business, which, we believe can grow, much faster than the other, segments. Historically, the gross margins, in this business, is, upwards of 50%. We are looking at promoting Animal Health and Nutrition products very aggressively in the coming quarters, and focusing on a few products which are, coming up newly. Correct. Secondly, given that we are seeing volumes have been rather stable, what we have lost is it purely because of pricing? What would be our current capacity utilization across plants or across segments? Would you be requiring to put up more capacity over the next two to three years depending on your projections of the revenue growth and volume growth? Currently, our capacity utilization this year has been around, you know, average of about 55% odd. We have enough headroom now in our facilities. Both, in Rossari as well as in our two subsidiaries. I think immediately over the next couple of years, we do not plan to put in any large CapEx for any kind of an expansion. We have enough room within our current infrastructure to, you know, almost do a double up the turnover. Currently no plans of any further expansions. All right. Thank you. Thank you so much for this and all the very best. Thank you. Thank you. A reminder to participants to press star and one to ask a question. We have a question from the line of Mahesh Vaya from UTI Mutual Fund. Please go ahead. Yeah, thank you, sir. Good evening. Sir, where do you think, how you think on your AHN business and HPPC business over three years down the line? The second question is on, do you face any major challenge in your textile finished business? Yes. We are expecting the HPPC business to double in three years, three to four years, and AHN to definitely double in three years or more. In two years, Ketan sir is saying, AHN business. Textile business, we are expecting to double in four to five years. What is our plan, till now, we are on track, except, you know, for the Ukraine war, we had something down in the subsidiaries. I think, in three to four years, we should double sales, what we have now. Sure, sir. Thank you. What are the capacity utilization across the levels, all three segments? Currently, as I said, we are at about 55% kind of capacity utilization. Okay. Okay. Sure. Sure. Thank you. Thank you, Mr. Vaya. A reminder to participants to press star and one to ask a question. We have a question from the line of Harsh Shah from Nuvama Wealth Management. Please go ahead. Thank you for the opportunity. Sir, my question is on HPPC segment. In investor presentation, you have mentioned that the degrowth in HPPC was majorly attributable to the degrowth in the subsidiaries. Sir, can you quantify how much degrowth in on standalone basis and how much was on in subsidiary level? Sorry, what was your last question? How much was on? Can you quantify, sir, how much degrowth was attributable to subsidiary and how much degrowth was attributable on the standalone level? Majorly the degrowth that has happened is on the subsidiaries front. There is what about 9% kind of degrowth that we've seen in this quarter over Q2. Majorly is because of the lower demand in the agro part and lower off take from the exports of Tristar. These two have been the major causes for this drop. All right. Okay. Thanks so much. Thank you. Ladies and gentlemen, to ask a question, please press star and one on your phone. We have a question from the line of Rohit Nagraj from Centrum Broking. Please go ahead. Thanks for the follow-up. In terms of integration, the integration of the two subsidiaries, is it completely done now? Are we able to accrue any benefits from the same? Thank you. I think I have touched upon this in my opening remarks. If you see the performance of the two subsidiaries, they've done exceptionally well on a year-on-year YTD basis. I think much of this could happen because of Rossari coming into the picture and a lot of these synergistic plans which we had put in are slowly are visible. Be it in, you know, our operations, you know, production activities, R&D, even on the business development and sales front, I think the teams are working very coherently, and building the Rossari brand across all the three companies. I think more of this. We are seeing an improvement on this, and I think going forward, you will see these aspects playing out further in the next few quarters and few years. I think most of it's a developmental activity and you'll keep seeing this improvement going forward. Say, for example, Rohit, in certain product ranges like the skin finish. The synergy happened between Unitop and Rossari. For the regenerated cellulose additives, again, Unitop and Rossari. If you look at silicone wetter. The silicone wetter was a combination between all the three companies, Tristar, Unitop and Rossari. If you see for many product ranges, the synergy has played out very well. Apart from that, the non-agro business has been really stimulated by the presence of Rossari and their network in both India as well as in the export market. From the product synergy part of it, we have done extremely well. Of course, HR and finance and other departments, there was a complete integration in the first six to eight months itself. Right, sir. Thank you. sir, just one doctor keeping question. In terms of maintenance CapEx on a consolidated basis, what would be the number for FY 23 and FY 24? During nine months, what would be the exports%? Thank you. Nine months exports means? Yeah, exports as a percentage of sales on a consolidated basis. On a consolidated basis, our exports are about 25%, 26%, 25% in. Nine months. In nine months. Twenty-four. 24%, yeah. Ninety-three. Our CapEx spend, I think during this would be. Consolidated would be five. About INR 5 crores-INR 10 crores kind of. Not much. Okay. Next year also similar run rate would be there because our capacities are... Around that INR 10-12 crores. We may do some small projects here and there. Although overall we don't expect to spend more than INR 30-40 crores kind of number. Sure, sure. Thanks a lot. Thanks a lot and best of luck, sir. Thank you. Thank you. Thank you. A reminder to participants to press star and one to ask a question. We have a question from the line of Aman Shah from Jita Investments. Please go ahead. Hello. Thank you for the opportunity, sir. My question is on volume growth I just missed. What was the volume growth on a year-on-year basis in subsidiary and standalone in this quarter, sir? I think we've already talked about this earlier. The fall in revenue that you are seeing in consolidated is most of it is due to the fall in subsidiary volumes. That 9% odd fall in the consolidated revenue, most of it is attributable to the volume degrowth. Okay. No, because the prices have dropped, should we like the volume degrowth also is similar to value degrowth on overall basis? Yeah. Some part of the raw material price fall we are seeing in that's more visible in the standalone revenue where more than the volume, this fall slightly has happened because of the price corrections that we have done. Not in the subsidiaries, that's not the case. Okay. Okay. Sir, for next year we are giving, like a 15%-20% should be the revenue growth and with better margins. How should we look at the margin level? Like this year we are giving a guidance of 13% that we will close at for full year EBITDA, considering INR 220 crores is what you said. 16%-17% is what we think will happen over a two-year period as we embark on the high profitability products. For next year, should we work with a 14%-15% margin? Would you think that's a fair assessment? Yes. As an assessment you can do that. As I said, we will be moving towards like 16%, 17%. I don't want to give you a number as such, but, the movement will be from 13%-17% over the next two years. Okay. Okay. Sir, the third is in subsidiaries part, we have total breakup on the consolidated sales between HPPC, Textile and AHN business. In subsidiary, most of it will be part of HPPC? Yes. Yes. Okay. Okay. Now just fourth question is on competition, we always say that we don't compete directly with our vendors. We actually take product from our vendor and improve on their products to make it customized for our customer. Who exactly is our class of competitors? That I want to understand. Is it like the customer itself does all these things at its own end, that we actually give that service to the customer? Because if we are not competing with our vendors, and I don't know much of who can be our direct competitor except on the textile part. If you can help me understand who are our class of competitors, whether the work that the client itself is doing, that we are actually helping him do that work. Aman, namaste. I'm Chari here. Namaste. Uh, so, uh, in terms of competition, if you see animal nutrition, uh, we have Kemin, Cargill, Novus, Alltech, uh, but, uh, you know, uh, Jubilant, Zydus, Cadila, Zoetis. Uh, these are the kind of, uh, competitors, uh, we face in animal nutrition. Uh, in the HPFC segment, uh, you know, uh, we should-- we always have given that Dow, BASF, Croda, uh, Solvay, uh, these are the kind of competitors. SNF is a, is a, is the one we face. And in textiles, uh, we have again the multinationals like Archroma, Huntsman, uh Croda, CHT and Pulcra. Uh, so basically we go for, uh, premium, uh, niche products and, uh, we try to give value-added solutions where we try to reduce either the process cost or the process time, uh, or make their process more sustainable in terms of reducing, uh, T-TDS or BOD or C-COD. All in all, making the customers more sustainable is a focus for us either in terms of green chemistry or in terms of cost. Okay, okay. Basically also if I can understand, I think agility and giving the product at the fastest pace and the solution at a very fast pace is on a sustainable basis is also our one of our advantages. That would be right way to put against all these competitors. Yeah, that is true. That because that is our backbone formulation, and giving customer a customized solution with our center of excellence at IIT Powai, that is one of the key differentiators that Rossari has with its competition. The speed with which and the flexibility with which our teams are tuned to work, that also differentiates Rossari. If you ask somebody in the market, then you will note, notice that Rossari can really deliver solutions and products to the market much faster than most of our competitors. Awesome. Okay. Okay. Thank you so much. Thank you, Aman. Thank you. Ladies and gentlemen, to ask a question, please press star and one on your phone. Participants may please press star and one to ask a question. We have a question from the line of Ashit Kothari, an individual investor. Please go ahead. Good evening, sir. Just, follow up to the earlier question on competition. If you have to say that, top two competitors in each segment, top two competitors to the company. What we believe, as you know, we are one of the speakers or the ones who asked questions said that we don't compete, co-companies supplying similar kind of products, the top ones which I mentioned, like in terms of acrylic agents or surfactants, companies like BASF, Solvay, Croda, Dow, these are some very, very good ones who we consider as competitors. People who copy us, we don't consider them as our competitors. Textiles, again, Archroma, Huntsman, Croda, these are companies and BASF are companies we admire. In terms of animal nutrition, Kemin, Alltech, Novus, these are three companies we admire. On, what, on what criteria we beat them? What, criteria? What did you say, sir? In which criteria we beat them? We focus on giving value-added formulations, which can reduce, you know, their process time or process cost or, you know, make them more sustainable. For example, if there is a, you know, product used in detergents, can we reduce the cost of the detergent or give better cleaning property, better shine to the cloth, or make it more greener, more sustainable detergent? That would be the way we work in our R&D lab at IIT Powai. That is what has helped us reached this stage, you know, in our company's growth cycle. We have zero effluent in all our plants? No, zero effluent. No, we have, as a company, our focus is always on products which produce zero effluent. We have to wash, because as a specialty chemical company, we have more than 5,000 products on our range. When we change over from one product to another, definitely there is washing and then washing has to be treated. So we have permissions at the edge, for the requisite treatments. Discharge, we don't discharge at all. At the edge only we have discharge permission. It means that our water consumption is more change, product change, our water consumption will be always higher, and we cannot be 0%, I mean, say 0% in terms of water consumption. That is all whatever water we consume, we recycle, we reuse so that we are net zero on water consumption. We are a very green company, as you said. Majority of the products do not generate any effluent. Right. If you see our chemistry, we are into enzyme, silicone, acrylic and surfactant. These four chemistries are very, very good and green chemistries in terms of comparison. We don't do any hazardous processes, like chlorination, nitration, halogenation or amination, in a big way. Our processes are more epoxidation, peroxidation, polymerization and distillation and effluent is not generated mostly in this. we can say our products are green products and we can earn carbon credits in this case? Yeah. We do that. We have a calculation for earning carbon credits, yes, sir. How much of earning contribution and over a period of next five years, carbon credits can become a part of our profitability? No, I don't think that's anything major. Not major. No, it's not major. All right, sir. Thanks a lot. Thank you. Thank you. Thank you. As there are no more questions, I now hand the conference over to the management for closing comments. Over to you, sir. Thank you everyone for your patient hearing. I hope we have been able to answer all your questions satisfactorily. Should you need any further clarifications or would like to know more about the company, please feel free to contact our team or CDR India. Thank you once again for taking the time to join us on this call, and have a nice day. Thank you. On behalf of Rossari Biotech Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.